Kiniksa Pharmaceuticals, Ltd. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Kiniksa Pharmaceuticals, Ltd. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial performance, equity plans, and key business agreements.</b>

AI Summary

Kiniksa Pharmaceuticals, Ltd. (KNSA) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Kiniksa Pharmaceuticals, Ltd. filed a 10-Q report for the period ending March 31, 2024. The filing details financial information including retained earnings, additional paid-in capital, and accumulated other comprehensive income for various periods. Information on equity incentive plans, employee stock options, and restricted stock units is provided as of March 31, 2024. The report references collaboration agreements for Vixarelimab and Rilonacept, as well as product sales for the periods ending March 31, 2024, and March 31, 2023. Key agreements include a Clinical Supply Agreement with Regeneron Pharmaceuticals Inc. and an Asset Purchase Agreement with Biogen MA.

Why It Matters

For investors and stakeholders tracking Kiniksa Pharmaceuticals, Ltd., this filing contains several important signals. This filing provides investors with the latest financial snapshot of Kiniksa Pharmaceuticals, including changes in equity and details on stock-based compensation, crucial for valuation and investment decisions. The disclosure of ongoing collaboration and licensing agreements, along with product sales data, offers insight into the company's revenue streams and strategic partnerships, impacting future growth prospects.

Risk Assessment

Risk Level: low — Kiniksa Pharmaceuticals, Ltd. shows low risk based on this filing. The filing is a standard 10-Q, which is a routine financial disclosure for publicly traded companies, indicating no immediate or unusual risks are highlighted within this specific document type.

Analyst Insight

Monitor future 10-Q filings for trends in revenue growth, profitability, and updates on the progress of key collaboration agreements.

Key Numbers

• 2024-03-31 — Report Period End Date (10-Q filing)
• 2024-04-25 — Filing Date (10-Q filing)

Key Players & Entities

• Kiniksa Pharmaceuticals, Ltd. (company) — Filer of the 10-Q report
• Regeneron Pharmaceuticals Inc. (company) — Party to a Clinical Supply Agreement
• Biogen MA (company) — Party to an Asset Purchase Agreement
• Beth Israel Deaconess Medical Center Inc. (company) — Party to a License Agreement

FAQ

Industry Context

Kiniksa Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapeutics.

Regulatory Implications

As a publicly traded company, Kiniksa Pharmaceuticals is subject to SEC regulations, including the requirement to file quarterly reports (10-Q) to disclose financial and operational information.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management's discussion and analysis.
2. Analyze the company's equity structure and stock-based compensation details for potential impact on shareholder value.
3. Investigate the terms and progress of the mentioned collaboration and licensing agreements for future revenue potential.

Key Dates

• 2024-03-31: Quarterly Period End — Financial data reported in the 10-Q pertains to this date.
• 2024-04-25: Filing Date — Date the 10-Q was officially submitted to the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from previous filings.

Key Financial Figures

• $0.000273235 — 05,405 Class A common shares, par value $0.000273235 per share 1,795,158 Class B common sh

Filing Documents

• knsa-20240331x10q.htm (10-Q) — 1858KB
• knsa-20240331xex10d1.htm (EX-10.1) — 73KB
• knsa-20240331xex10d2.htm (EX-10.2) — 76KB
• knsa-20240331xex31d1.htm (EX-31.1) — 11KB
• knsa-20240331xex31d2.htm (EX-31.2) — 10KB
• knsa-20240331xex32d1.htm (EX-32.1) — 6KB
• knsa-20240331xex32d2.htm (EX-32.2) — 6KB
• 0001558370-24-005774.txt (&nbsp;) — 7478KB
• knsa-20240331.xsd (EX-101.SCH) — 50KB
• knsa-20240331_cal.xml (EX-101.CAL) — 49KB
• knsa-20240331_def.xml (EX-101.DEF) — 248KB
• knsa-20240331_lab.xml (EX-101.LAB) — 432KB
• knsa-20240331_pre.xml (EX-101.PRE) — 347KB
• knsa-20240331x10q_htm.xml (XML) — 1150KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 7

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 7 Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 7 Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 8 Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2024 and 2023 9 Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 10

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

— OTHER INFORMATION

PART II — OTHER INFORMATION 40

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 109

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 109

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 109

Other Information

Item 5. Other Information 109

Exhibits

Item 6. Exhibits 110

SIGNATURES

SIGNATURES 111 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report"), contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report including statements regarding our commercial strategy; potential value drivers; potential indications; potential market opportunities and competitive position; ongoing, planned and potential clinical trials and other studies; timing and potential impact of clinical data; future results of operations and financial position; expected timeline for our cash, cash equivalents and short-term investments; product development; prospective products and product candidates; supply of drug products at acceptable cost and quality; collaborators, license and other strategic arrangements; the expected timeline for achievement of our clinical milestones; potential marketing authorization from the U.S. Food and Drug Administration (the "FDA") or regulatory authorities in other jurisdictions; potential and ongoing coverage and reimbursement for our products and product candidates, if approved; clinical and commercial activities; research and development costs; timing of regulatory filings and feedback; timing and likelihood of success; and plans and objectives of management for future operations and funding requirements, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "goal," "design," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or

— Financial Information

Part I — Financial Information

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 141,078 $ 107,954 Short-term investments 72,474 98,417 Accounts receivable, net 15,995 21,266 Inventory 27,278 31,122 Prepaid expenses and other current assets 13,766 17,538 Total current assets 270,591 276,297 Property and equipment, net 712 734 Operating lease right-of-use assets 12,324 11,931 Other long-term assets 4,128 827 Intangible asset, net 17,000 17,250 Deferred tax assets 214,918 219,283 Total assets $ 519,673 $ 526,322 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 5,632 $ 8,246 Accrued expenses 44,718 44,667 Deferred revenue 156 307 Operating lease liabilities 2,279 2,253 Other current liabilities 11,427 8,193 Total current liabilities 64,212 63,666 Non-current liabilities: Non-current deferred revenue 11,811 11,954 Non-current operating lease liabilities 9,864 10,005 Other long-term liabilities 1,891 1,858 Total liabilities 87,778 87,483 Commitments and contingencies (Note 13) Shareholders' equity: Class A common shares, par value of $ 0.000273235 per share; 40,184,356 shares and 35,781,373 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 11 10 Class B common shares, par value of $ 0.000273235 per share; 1,795,158 shares issued and outstanding as of March 31, 2024 and December 31, 2023 1 1 Class A1 common shares, $ 0.000273235 par value; 12,781,964 and 16,826,468 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 4 5 Class B1 common shares, $ 0.000273235 par value; 16,057,618 shares issued and outstanding as of March 31, 2024 and December 31, 2023 4